Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig

20031,052 citationsJournal Articlebronze Open Access

Authors

Joel M. Kremer · Center for Rheumatology

René Westhovens · Universitair Ziekenhuis Leuven

Marc Léon · CHU Ambroise Paré

Eduardo Di Giorgio · National University of Quilmes

Rieke Alten · Schlosspark-Klinik

Serge Steinfeld · Erasmus Hospital

Anthony S. Russell ·

Abstract

In patients with active rheumatoid arthritis who were receiving methotrexate, treatment with CTLA4Ig significantly improved the signs and symptoms of rheumatoid arthritis and the health-related quality of life. CTLA4Ig is a promising new therapy for rheumatoid arthritis.

Topics & Keywords

Monoclonal and Polyclonal Antibodies Research T-cell and B-cell Immunology Rheumatoid Arthritis Research and Therapies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 349, Issue 20, pp. 1907-1915

DOI: 10.1056/nejmoa035075

Field-Weighted Citation Impact: 74.79